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Background: Warfarin is used as an anticoagulant to prevent stroke in patients with atrial fibrillation (AF), however it is associated with increased 
risk of bleeding. It is still debatable whether chronic kidney disease (CKD) patients undergoing dialysis should be treated with warfarin. We aimed to 
investigate the association between CKD patients on dialysis and the risk of stroke and bleeding in AF patients treated or not treated with warfarin.
methods: We conducted a population-based cohort study of patients aged 65 years or older admitted to hospital with a diagnosis of AF, in Quebec, 
Canada, during 1999 to 2007. We used linkage between hospital discharge databases, physicians, and prescription drug claims. We evaluated the 
association between CKD patients on dialysis and stroke and bleeding events with regard to warfarin usage.
results: Of 83,513 AF patients, 1039 (1.2 %) were on dialysis. Dialysis patients were younger but had higher mean CHADS2 score (2.2 vs. 1.9). 
In multivariable Cox-regression analyses, among warfarin users, the risk of stroke in dialysis patients tended to be higher compared to patients not 
on dialysis (HR: 1.39 95%CI: 0.95, 2.04), however it did not reached statistical significance (Table 1). Bleeding risk was higher in dialysis patients, 
regardless of warfarin use.
conclusions: Dialysis patients treated with warfarin tend to have higher risk of stroke compared to patients not undergoing dialysis. Further 
research in larger populations of dialysis patients is required. 
Table 1: Multivariable Cox Regression Models for the Risk of Stroke and Bleeding Among Patients with Atrial Fibrillation Under Dialysis
HR for Stroke HR for Bleeding
All population1
Total population n= 83513
Dialysis patients n= 1039
1.28 (0.97, 1.68) 1.91 (1.49, 2.45)
Warfarin users2 
Total population n= 49654
Dialysis patients n= 544
1.39 (0.95, 2.04) 2.06 (1.50, 2.82)
Non warfarin users2 
Total population n=33859
Dialysis patients n= 495
1.15 (0.78, 1.70) 1.65 (1.11, 2.46)
1 Models were adjusted for: female sex, age (years), co-morbidities, components of CHADS2 score, warfarin treatment, rate control drugs, rhythm 
control drugs, ASA, Clopidogrel, NSAIDS (within 30 days), length of hospitalization and type of AF diagnosis (primary vs. secondary).
2 excluding adjustments for warfarin treatment.
